帕博利珠单抗免疫治疗复发性、耐药性子宫内膜癌后的长期持久反应。
Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer.
作者信息
Chan John K, Lakomy David S, McDonald Yassmina, Kapp Daniel S
机构信息
Division of Gynecologic Oncology, Palo Alto Medical Foundation / California Pacific / Sutter Research Institute, Palo Alto, CA, USA.
Dartmouth Geisel School of Medicine, Dartmouth College, Hanover, NH, USA.
出版信息
Gynecol Oncol Rep. 2020 May 26;33:100581. doi: 10.1016/j.gore.2020.100581. eCollection 2020 Aug.
•Recurrent resistant uterine cancer patients have a poor prognosis with limited treatment options.•Pembrolizumab is a PD1-inhibitor that was recently FDA approved for MMR-deficient solid tumors, including uterine cancer.•Pembrolizumab can produce long-term durable response in resistant, refractory endometrial cancer with minimal side effects.
•复发性耐药子宫癌患者预后较差，治疗选择有限。
•帕博利珠单抗是一种PD1抑制剂，最近被美国食品药品监督管理局（FDA）批准用于治疗包括子宫癌在内的错配修复缺陷实体瘤。
•帕博利珠单抗可在耐药、难治性子宫内膜癌中产生长期持久反应，且副作用极小。
Zotero 插件